OpGen, Inc. (OTC:OPGN) Q1 2021 Earnings Conference Call May 13, 2021 8:30 AM ET Company Participants Megan Paul - IR Oliver Schacht - President and CEO Tim Dec - CFO Conference Call Participants Yi Chen - H.C. Wainwright Maxim Jacobs - Edison Group Ben Haynor - Alliance Global Operator Good morning and thank you for joining us today. I would now like to hand the call over to Megan Paul of Investor Relations. Megan, the floor is yours. Megan Paul Welcome to the OpGen First Quarter 2021 Earnings Call and Busi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ______________________ FORM 10-K ______________________ (Mark one) ☒ ANNUAL REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2020 ☐ TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from _______ to _______. Commission file number 001-37367 ______________________ OPGEN, INC. (Exact name of registrant as specified in it ...

OpGen, Inc. (OTC:OPGN) Q4 2020 Earnings Conference Call March 25, 2021 4:30 PM ET Company Participants Oliver Schacht – President and Chief Executive Officer Tim Dec – Chief Financial Officer Conference Call Participants Max Jacobs – Edison Group Ben Haynor – Alliance Global Partners Operator Welcome to the OpGen Fourth Quarter and Full Year 2020 Earnings Call and Business Update. At this time, all participants are in listen-only mode. Following management’s prepared remarks, there will be a Q&A session. As ...

OpGen, Inc. (OTC:OPGN) Q3 2020 Earnings Conference Call November 11, 2020 4:30 PM ET Company Participants Megan Paul - IR Oliver Schacht - CEO, President & Director Timothy Dec - CFO & Corporate Secretary Conference Call Participants Maxim Jacobs - Edison Group Yi Chen - H.C. Wainwright & Co. Benjamin Haynor - Alliance Global Partners Operator Greetings. Welcome to the OpGen, Inc. Third Quarter 2020 Earnings Conference Call. [Operator Instructions]. I will now turn the conference over to your host, Megan Pa ...

Start Time: 16:30 January 1, 0000 5:18 PM ET OpGen, Inc. (OTC:OPGN) Q2 2020 Earnings Conference Call August 12, 2020, 16:30 PM ET Company Participants Oliver Schacht - CEO Tim Dec - CFO Megan Paul - IR Conference Call Participants Maxim Jacobs - Edison Group Ben Haynor - Alliance Global Yi Chen - H.C. Wainwright Operator Greetings, and welcome to the OpGen Incorporated Conference Call. [Operator Instructions]. It is now my pleasure to introduce your host, Megan Paul, Investor Relations. Please go ahead. Meg ...

Start Time: 16:30 January 1, 0000 5:13 PM ET OpGen, Inc. (OTC:OPGN) Q1 2020 Earnings Conference Call May 07, 2020, 16:30 PM ET Company Participants Oliver Schacht - CEO Tim Dec - CFO Joe Green - Managing Director of IR Conference Call Participants Wiktoria OÂ'Hare - Edison Investment Research Ben Haynor - Alliance Global Partners Yi Chen - H.C. Wainwright Operator Mr. Green, you may begin. Joe Green Thank you. Welcome to the OpGen First Quarter 2020 Earnings Call and Business Update. At this time, all parti ...

Start Time: 16:30 January 1, 0000 5:18 PM ET OpGen, Inc. (OTC:OPGN) Q4 2019 Earnings Conference Call March 24, 2020, 16:30 PM ET Company Participants Evan Jones - Chairman and CEO Tim Dec - CFO Oliver Schacht - CEO Curetis Joe Green - Managing Director of IR Conference Call Participants Yi Chen - H.C. Wainwright Ben Haynor - Alliance Global Partners Maxim Jacobs - Edison Group Bruce Jackson - The Benchmark Company Operator Ladies and gentlemen, thank you for standing by. Welcome to the Fourth Quarter 2019 O ...

Financial Data and Key Metrics Changes - Total revenue for the first nine months of 2019 increased by 22% to $2.7 million compared to $2.2 million in 2018 [7] - Third quarter revenue was $648,000, a 17% increase from $552,000 in the prior year period [7] - Net loss for the third quarter of 2019 was $3.5 million, or $3.95 per share, compared to a net loss of $3.3 million, or $10.67 per share in the third quarter of 2018 [20] - Total operating expenses for the nine months ended September 30, 2019, were $12.4 million, up from $11.7 million in the same period of 2018 [21] Business Line Data and Key Metrics Changes - Revenue from RUO Acuitas AMR Gene Panel and Acuitas Lighthouse related products represented 43% of total revenue, amounting to $1.2 million, up from less than 5% in the comparable 2018 period [18] - R&D expenses for the first nine months of 2019 were $4.1 million, up from $3.8 million in 2018 [22] - G&A expenses were $4.9 million, down from $5.4 million in 2018 [22] Market Data and Key Metrics Changes - Curetis has a portfolio of five CE marked in vitro diagnostic products marketed through distribution partners in Europe, the Middle East, and some Asian markets [9] - The combined company is expected to have a pro forma 2019 revenue in the range of $5 million to $6 million, with anticipated growth to $10 million to $15 million in 2020 [27] Company Strategy and Development Direction - The strategic focus includes gaining regulatory clearances, establishing market positions for proprietary molecular diagnostic testing platforms, and leveraging global commercial capabilities [13] - The combination with Curetis aims to create a market leader in infectious disease and antimicrobial resistance detection, enhancing operational efficiencies and financial discipline [34][31] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the completion of the business combination with Curetis, expecting it to close by late January or early February 2020 [26] - The company is committed to improving shareholder value and capturing financial synergies associated with the merger [31][32] Other Important Information - The company closed the public offering of 4.7 million units at $2 per unit, raising gross proceeds of $9.4 million [23] - The company regained compliance with NASDAQ's shareholder equity requirement and minimum bid price rule [24] Q&A Session Summary Question: Timing for commercialization of Acuitas AMR Gene Panel after 510(k) clearance - Management indicated that commercialization would likely start one to two months after clearance, aligning with the merger with Curetis [46] Question: Timeframe for completion of clinical studies for urine panel - Management expects to complete the urine trial phases by early 2020 [48] Question: Financial runway for the combined company post-merger - The combined company is expected to have a financial runway reaching into Q2 of the following year [54] Question: Conditions for closing the transaction with Acuitas - Key conditions include completing financing and gaining shareholder approvals, with optimism for successful closure [55][56] Question: Expected R&D spending trends - R&D spending is expected to increase modestly in Q4 and ramp up significantly in Q1 of the following year [66]

OpGen, Inc. (OTC:OPGN) Q2 2019 Results Earnings Conference Call August 7, 2019 4:30 PM ET Company Participants Evan Jones - Chairman and Chief Executive Officer Tim Dec - Chief Financial Officer Conference Call Participants Nathan Weinstein - Aegis Capital Ben Haynor - Alliance Global Operator Welcome to the OpGen Second Quarter 2019 Conference Call. At this time, all participants are in a listen-only mode. Following management's prepared remarks, they were hold ex-U.S. Q&A session. As a reminder, this conf ...

OpGen, Inc. (OTC:OPGN) Q1 2019 Earnings Conference Call May 14, 2019 4:30 PM ET Company Participants Evan Jones - Chairman and Chief Executive Officer Timothy Dec - Chief Financial Officer Conference Call Participants Edward Marks - H.C. Wainwright & Co. Nathan Weinstein - Aegis Capital Corporation Maxim Jacobs - Edison Group Benjamin Haynor - Alliance Global Partners Anthony Polak - Aegis Capital Corp. John Power - Redwood MicroCap Fund Inc. Operator Welcome to the OpGen First Quarter 2019 Conference Call. ...